You might see a little bounce but the market is definitely building up momentum on the downside and looks like this is going to be a serious bloodbath for investors over the next few months.
I would recommend hedging with puts.
There is even one stock that is on its butt now but will probably return over 300 times invested dollars in the next 36 months . . . AMPE . . . check it out . . . 3 pivotal clinical trials all starting in the next 60 days for blockbuster drugs and the trials are al exceptionally low risk because the drugs have already been approved by the FDA for different illnesses. And over 20 million in cash to cover through mid 2014. Big licensing deals coming soon and FDA approvals and on and on.
This one is going to surprise very BIG and very soon!
Can Ampio's New Science Take A Big Bite Out Of The $60 Billion Anti-Inflammatory Market? [View article]
There is nothing suspicious. If you read earlier press releases you will see that Ampion worked immediately and that it was followed up by the trial investigators at day 30 and day 84 only as a measurement point.
Can Ampio's New Science Take A Big Bite Out Of The $60 Billion Anti-Inflammatory Market? [View article]
Great article! Don't forget the over $20 million cash the company has in the bank to get through its trials. Ampion appears destined to soon become a huge factor in the anti-inflammatory market.
The Stock Market Rebound Is Coming [View article]
I would recommend hedging with puts.
There is even one stock that is on its butt now but will probably return over 300 times invested dollars in the next 36 months . . . AMPE . . . check it out . . . 3 pivotal clinical trials all starting in the next 60 days for blockbuster drugs and the trials are al exceptionally low risk because the drugs have already been approved by the FDA for different illnesses. And over 20 million in cash to cover through mid 2014. Big licensing deals coming soon and FDA approvals and on and on.
This one is going to surprise very BIG and very soon!
Hep C Competitors Cede Space To Gilead And Bristol-Myers And Turn To Niche Uses [View article]
Medical Advances May Help Improve Psoriasis Outcomes [View article]
The Quest For 100% Yield On Cost [View article]
AutoNavi Q3 Earnings Preview: Mobile/LBS In Focus; Attractive Takeover Target [View article]
5 Stocks To Trade, What's Next For The Market [View article]
4 High-Growth Internet Stocks To Buy, 1 To Avoid [View article]
Valeant: Top Hedge Fund Managers Like This Medical Stock [View article]
This Big Pharma Should Outperform Its Sector This Quarter [View article]
5 Healthcare Companies With Insider Buying During November 2012 - Part III [View article]
Owners Like Low Prices: Why Buffett And Munger Want IBM's Price To 'Languish' [View article]
$BRK-B SPECIAL ALERT http://bit.ly/SX6cql
The Only 20 Companies That Matter [View article]
Can Ampio's New Science Take A Big Bite Out Of The $60 Billion Anti-Inflammatory Market? [View article]
Can Ampio's New Science Take A Big Bite Out Of The $60 Billion Anti-Inflammatory Market? [View article]
Can Ampio's New Science Take A Big Bite Out Of The $60 Billion Anti-Inflammatory Market? [View article]